Cost Analysis of Supracervical Versus Total Hysterectomy During Sacrocolpopexy

View at publisher
Authors: Dora Jericevic, Victoria M. Li, Rui Wang, Moiuri Siddique, Nirit Rosenblum, Lauren E. Stewart
Cited by: 0
References: 46

Abstract

IMPORTANCE: A cost analysis model of supracervical (SCH) versus total hysterectomy (TH) at the time of minimally invasive sacrocolpopexy (SCP) has not been established. OBJECTIVES: Minimally invasive sacrocolpopexy (SCP), a mesh-augmented pelvic organ prolapse (POP) repair, is frequently performed with concomitant hysterectomy, either a supracervical hysterectomy (SCH) or total hysterectomy (TH), with comparable POP outcomes with either approach. However, for SCH versus TH, there are important implications on cervical cancer screening and reported complication rates. Clinical outcomes data have not identified a clear preferred hysterectomy type at the time of SCP. This study aimed to perform a cost analysis to compare SCH versus TH at the time of SCP for POP. STUDY DESIGN: A health care sector-perspective analysis was performed using a 10-year time horizon. Our model assumes that there is similar efficacy and patient satisfaction for SCH and TH, and that the age of patients undergoing SCP is 55 years (median age in the literature). The average cost of procedures and complications were estimated from publicly available data sources. Base-case probabilities for various complications were estimated through a PubMed literature search. RESULTS: TH-SCP is $654 less costly per treatment case compared with SCH-SCP ($26,101 vs. $26,754). Three model variables have the potential to reverse this cost advantage when varied across their ranges: SCH-SCP surgery, TH-SCP surgery, and the cost of cervical screening. Based on our model assumptions, SCH-SCP was 2.5% more costly than TH-SCP in relative terms. CONCLUSION: SCH-SCP was found to be more costly over a 10-year time horizon than TH-SCP in our study population.

Fields of Study & Subjects

Pelvic floor disorders treatments Uterine Myomas and Treatments Health Systems Economic Evaluations Quality of Life

Publication details

Journal / source
Urogynecology
Volume
32
Issue
3
Pages
180–189
Publication date
12 January 2026
Language
EN